A5076108356- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 epidemiological studies
- COVID-19 and healthcare impacts
- COVID-19 diagnosis using AI
- SARS-CoV-2 detection and testing
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- Otolaryngology and Infectious Diseases
- Health disparities and outcomes
- Kawasaki Disease and Coronary Complications
- Viral gastroenteritis research and epidemiology
- Escherichia coli research studies
- Hepatitis C virus research
- Climate Change and Health Impacts
- Hepatitis B Virus Studies
- Diabetes and associated disorders
- Chronic Disease Management Strategies
- Food Safety and Hygiene
- Health, psychology, and well-being
- Healthcare Systems and Public Health
- Chronic Obstructive Pulmonary Disease (COPD) Research
- HIV/AIDS Research and Interventions
European Centre for Disease Prevention and Control
2017-2025
Public Health England
2017-2019
Surrey and Sussex Healthcare NHS Trust
2018
In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020. We detail first cases. As at 21 February, nine countries reported 47 Among 38 cases studied, were linked to two clusters in Germany and France, 14 infected China. Median case age 42 years; 25 male. Late detection of clusters’ index delayed isolation further local 5 March, there 4,250
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant reported by seven European countries. COVID-19 with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, CI: 2.1–6.2; P.1: 2.6, 1.4–4.8) B.1.1.7/SGTF also intensive care admission 2.3, 1.4–3.5; 2.2, 1.7–2.8).
Since December 2019, over 1.5 million SARS-CoV-2-related fatalities have been recorded in the World Health Organization European Region - 90.2% people ≥ 60 years. We calculated lives saved this age group by COVID-19 vaccination 33 countries from 2020 to November 2021, using weekly reported deaths and coverage. estimated that averted 469,186 (51% of 911,302 expected deaths; sensitivity range: 129,851–733,744; 23–62%). Impact country ranged 6–93%, largest when implementation was early.
An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the 'Save PDF' action button.
Two months after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), possibility established and widespread community transmission in European Union Economic Area (EU/EEA) is becoming more likely. We provide scenarios for use preparedness a possible epidemic. The EU/EEA moving towards ‘limited sustained transmission’ phase. propose actions to prepare potential mitigation phases coordinate efforts protect health citizens.
The European monitoring of excess mortality for public health action (EuroMOMO) network monitors weekly all-cause in 27 countries or subnational areas. During the first wave coronavirus disease (COVID-19) pandemic Europe spring 2020, several experienced extraordinarily high levels mortality. is currently seeing another upsurge COVID-19 cases, and EuroMOMO again witnessing a substantial attributable to COVID-19.
We estimated risks of severe outcomes in 820,404 symptomatic paediatric COVID-19 cases reported by 10 European Union countries between August 2020 and October 2021. Case hospitalisation rates rose as transmission increased but were rare: 9,611 (1.2%) hospitalised, 640 (0.08%) required intensive care 84 (0.01%) died. Despite individual risk (adjusted odds ratio hospitalisation: 7.3; 95% confidence interval: 3.3–16.2; care: 8.7; 6.2–12.3) with comorbidities, most (83.7%) hospitalised children...
Since the end of November 2023, European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate 95.3 (95% CI: 91.7–98.9) all-cause deaths per 100,000 person-years for all ages. This is seen adults aged 45 years and older, coincides with widespread presence COVID-19, influenza respiratory syncytial virus (RSV) many countries during 2023/24 winter season.
We report an outbreak of invasive and non-invasive disease due to unusual type Streptococcus pyogenes (group A Streptococcus, emm66) among a vulnerable, largely homeless population in southern England Wales, detected September 2016. Twenty-seven confirmed cases were subsequently identified between 5 January 29 December 2016; 20 injected drugs six reported problematic alcohol use. To date, we have ruled out drug-related vehicles infection few common risk factors.
BackgroundAnnual seasonal influenza activity in the northern hemisphere causes a high burden of disease during winter months, peaking first weeks year.AimWe describe 2019/20 season and impact COVID-19 pandemic on sentinel surveillance World Health Organization (WHO) European Region.MethodsWe analysed weekly epidemiological virological data from primary care hospital sources reported by countries, territories areas (hereafter countries) Region.ResultsWe observed co-circulation...
The first documented British outbreak of Shiga toxin-producing Escherichia coli (STEC) O55:H7 began in the county Dorset, England, July 2014. Since then, there have been a total 31 cases which 13 presented with haemolytic uraemic syndrome (HUS). strain had toxin (Stx) subtype 2a associated an elevated risk HUS. This not previously isolated from humans or animals England. only epidemiological link was living having close links to two areas Dorset. Extensive investigations included testing and...
Abstract UK guidelines recommend routine HIV testing in high prevalence emergency departments (ED) and targeted for HBV HCV. The ‘Going Viral’ campaign implemented opt-out blood-borne virus (BBV) adults a ED, to assess seroprevalence, uptake, linkage care (LTC) rates staff time taken achieve LTC. Diagnosis status (new/known/unknown), current engagement care, severity of disease was established. LTC defined as patient informed plus ⩾1 clinic visit. A total 6211/24 981 ED attendees were tested...
Several SARS-CoV-2 variants that evolved during the COVID-19 pandemic have appeared to differ in severity, based on analyses of single-country datasets. With decreased testing and sequencing, international collaborative studies will become increasingly important for timely assessment severity new variants. Therefore, a joint WHO Regional Office Europe ECDC working group was formed produce pilot standardised study protocol estimate relative case-severity periods when two were co-circulating....
Background Progress towards HIV, hepatitis B virus (HBV) and C (HCV) elimination requires local prevalence estimates linkage to care (LTC) of undiagnosed or disengaged cases. Aim We aimed estimate seroprevalence, factors associated with positive blood-borne (BBV) serology numbers needed screen (NNS) detect a new BBV diagnosis achieve full LTC from emergency department (ED) testing. Methods During 9-month programme in an ED east London, England, testing was offered adult attendees having...
Despite high COVID-19 vaccine coverage in the EU/EEA, there are increasing reports of SARS-CoV-2 infections and hospitalisations vaccinated individuals. Using surveillance data from Estonia, Ireland, Luxembourg Slovakia (January-November 2021), we estimated risk reduction severe outcomes cases. Increasing age remains most important driver severity, vaccination significantly reduces all ages for hospitalisation (adjusted relative (aRR): 0.32; 95% confidence interval (CI): 0.26-0.39) death...
Prioritisation of elderly people in COVID-19 vaccination campaigns aimed at reducing severe outcomes this group. Using EU/EEA surveillance and uptake, we estimated the risk ratio case, hospitalisation death notifications 80 years older compared with 25-59-year-olds. Highest impact was observed for full uptake 80% or higher reductions notification rates cases up to 65% (IRR: 0.35; 95% CI: 0.13-0.99), hospitalisations 78% 0.22; 0.13-0.37) deaths 84% 0.16; 0.13-0.20).
Background Back to school (BTS) asthma has been previously reported in children; however, its epidemiology and associated healthcare burden are unclear. We aimed describe the timing magnitude of BTS using surveillance data from different health services England. Methods Asthma morbidity emergency department attendances general practitioner (GP) consultations between April 2012 December 2016 were used national syndromic systems Age-specific sex-specific rates time series peaks relative term...
There is a need for innovative methods to investigate outbreaks of food-borne infection linked produce with complex distribution network. The investigation large outbreak
Background Underlying conditions are risk factors for severe COVID-19 outcomes but evidence is limited about how risks differ with age. Aim We sought to estimate age-specific associations between underlying and hospitalisation, death in-hospital among cases. Methods analysed case-based data submitted The European Surveillance System 2 June 13 December 2020 by nine countries. Eleven cases only one condition the number of multimorbid were used as exposures. Adjusted odds ratios (aOR) estimated...
Abstract To guide evidence-based prevention of COVID-19 in children, we estimated risks severe outcomes 820,404 symptomatic paediatric cases reported by 10 EU Member States between August 2020 and October 2021. Case hospitalisation rates rose as overall transmission increased but were rare: 9,611 (1.2%) hospitalised, 640 (0.08%) required intensive care 84 (0.01%) died. Despite individual risk (aOR; 95% CI for hospitalisation: 7.3; 3.3 - 16.2, ICU: 8.7; 6.2 12.3) with comorbidities such...